Kevin O’Leary (AKA Mr. Wonderful) is a successful investor and entrepreneur known for his keen talent in finding unique opportunities across markets. His involvement in the psychedelics industry –with early positions in companies like MindMed and Compass Pathways– has been a key driver behind the sector’s accelerated growth.
Hear from Kevin as he lays down his perspective for understanding and investing in the psychedelics space.
Inspired by the groundbreaking research and expanding access to treatment, HealingMaps is on a journey to become the world’s most informative and trusted psychedelic-therapy search site. HealingMaps will provide content and information to patients to educate them on the alternatives available to legally treat their ailments, find clinics that can offer those services and buy products that can assist them in their healing journey.
Eleusis is an early mover in the psychedelics space with almost 10 years of activity since its launch in 2013. It recently signed an agreement to merge with Silver Spike Acquisition Corp. II (Nasdaq: SPKB), a SPAC, to an expected combined valuation of $446 million.
Hear CEO and co-founder Shlomi Raz describe the company’s vision to combine a comprehensive discovery and development platform with a chain of psychedelics-assisted therapy clinics.
With about 50 public companies and over 500 private ones, the psychedelics sector features a rich and complex catalog of diverse business profiles and growth strategies.
In this panel, a curated group of VC investors will share their blueprints for navigating the entire spectrum of the market.
Learn about the tools specialized investors use to differentiate unique opportunities in psychedelics.
Co-Founder & Partner
Palo Santo Fund
Dustin Robinson, Esq. CPA
Co-Founder & Managing Partner
Enveric Biosciences (NASDAQ: ENVB) is a neuroscience company developing next-generation psychedelic-inspired mental health medicines. Enveric’s robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD, and more.
Klee Irwin is an author, physicist and businessman who serves as CEO and Chairman of Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) as well as Director of Quantum Gravity Research (QGR), a non-profit research institute he founded in 2009.
His company Irwin Naturals is a household name and best-in-class herbal supplement formulator since 1994 that is leveraging its brand to enter the cannabis and psychedelic industries.
PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF) is a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates produced by genetically modified organisms targeting the potential treatment of mental health challenges, neurological disorders, and other human health conditions.
Successful cannabis entrepreneur and billboard-charting rapper Berner is all-in the psychedelics space. After building the iconic cannabis brand Cookies, Berner is expanding into the psychedelics space. In 2021, Berner launched Caps by Cookies, a line of capsules that combines functional mushrooms with cannabinoids and terpenes to achieve naturally-produced states of wellbeing. Hear Berner explain the company’s plans to dive into the psychedelics market in the near future.
Cybin (NYSE:CYBN) is a biopharmaceutical company working on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Filament Health (OTCQB:FLHLF) (NEO:FH) is a clinical-stage psychedelic drug development company creating safe, standardized, naturally-derived psychedelic medicines. Filament’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development, paving the way with the first-ever natural psychedelic drug candidates.
HMNC Brain Health is a precision psychiatry biopharma company developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The company develops a unique pipeline for targeting both major depressive disorder and treatment-resistant depression, and is now entering the next stage of its development with a large-scale licensing and fundraising agenda.
Bonaventure Equity is a venture capital firm focused on investing in the emerging life sciences verticals of the cannabis economy. Providing investment capital and resources, BVE partners with pioneering founders developing innovative science and technology in the biotech, healthcare, ag tech and psilocybin markets.
Wesana Health Holdings Inc. (CSE: WESA) (OTCQB: WSNAF) is a data-driven life sciences company focused on developing novel therapies to help people transcend barriers in mental health and performance. Wesana innovates in care development through therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model.
Publicly traded LFTD Partners Inc., Jacksonville, FL (OTCQB ticker symbol LIFD; www.LFTDPartners.com) is the parent corporation of Lifted Made, Kenosha, WI (www.LiftedMade.com), which manufactures and sells psychedelic products under the Silly Shruum brand, and hemp-derived cannabinoid products under the Urb Finest Flowers brand. LFTD Partners Inc. also owns 4.99% of CBD-infused beverage and products maker Ablis Holding Company (www.AblisBev.com), and of craft distillers Bendistillery Inc. d/b/a Crater Lake Spirits (www.CraterLakeSpirits.com) and Bend Spirits, Inc. (www.Bendistillery.com), all located in Bend, OR.
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Investing in the psychedelics industry is often described as a long-term play, but significant events are coming in the next 18 months that can spark a new wave of revenue generation and improved valuations for companies in the space. What are the next big catalysts in psychedelics?
Natalie Ginsberg, M.S.W.
Global Impact Officer
CEO & Founder
EI.Ventures/Psilly is a provider of plant-derived, regulatory approved psychoactive compounds intended to service both medicinal and therapeutic markets. The company engages in the research and development of psychoactive compounds such as DEA-registered psilocybin to empower customized compounds and personalized formulas, thereby providing botanical medicines in the psychedelic space for better mental wellness.
Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind Labs is developing novel pharmaceutical formulations of DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications.
Our Mission at Sanctuary Healthcare is to define and expand the standard of care in Psychedelic Medicine (PM) and Psychedelic Assisted Therapy (PAT), focusing on patient care, research, and advocacy
Felicity Pharma is a biotech company focused on using psychedelics for the treatment of mood disorders in women, passionate about changing the paradigm when it comes to women and their medical needs. Felicity creates real solutions for women with mood disorders by disrupting the existing antidepressant markets. The company’s working with novel psychedelic drugs to create solutions that are female-specific.